MOG (35-55) | CAS:149635-73-4

We serve MOG (35-55) CAS:149635-73-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
MOG (35-55)

Chemical Name:MOG (35-55)
CAS.NO:149635-73-4
Synonyms:MOG (35-55)
Myelin Oligodendrocyte Glycoprotein Peptide (35-55)
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Molecular Formula C118H177N35O29S
Molecular Weight 2581.950
Index of Refraction 1.678
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Myelin oligodendrocyte glycoprotein (MOG) 35-55 is a minor component of CNS myelin. Produces a relapsing-remitting neurological disease with extensive plaque-like demyelination, common to the manifestations of multiple sclerosis. Induces strong T and B cell responses and is highly encephalitogenic.



Contact us for information like MOG (35-55) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Myelin Oligodendrocyte Glycoprotein Peptide (35-55) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MOG (35-55) Use and application,Myelin Oligodendrocyte Glycoprotein Peptide (35-55) technical grade,usp/ep/jp grade.


Related News: “Ultimately, this is a public health decision,” she said, adding that the restrictions were precautionary measures to keep the country virus-free and contain the worldwide outbreak.6-bromohexanoic acid manufacturer Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs.1-[2-Chloro-4-(4-chlorophenoxy)phenyl]ethan-1-one supplier Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs.ethyl 6-bromopyridine-2-carboxylate vendor Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment.International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.